DNLI Earnings Date: Nov 3, 2026 (Estimated) — Denali Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is DNLI's next earnings date?
Denali Therapeutics Inc. (DNLI) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.32 on revenue of $12.2M.
How did DNLI do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Denali Therapeutics Inc. posted EPS of -$0.68 versus the -$0.51 estimate, a miss of 19.3%. Revenue was $3.6M against a $2.2M estimate. The stock's 1-day post-earnings move was +0.4%.
How much does DNLI stock move after earnings?
DNLI beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.7% (up or down) in the day after earnings.
About Denali Therapeutics Inc.
Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.51 | -0.68 | -19.30% | $3.6M | ❌ Miss | +0.40% | +0.36% | -9.91% |
| 2026-05-19 | Q1 2026 | -0.71 | -0.69 | +2.82% | $0 | ✅ Beat | +3.98% | +11.60% | +28.71% |
| 2026-02-26 | Q4 2025 | -0.75 | -0.73 | +2.67% | $0 | ✅ Beat | -1.12% | -8.03% | -15.22% |
| 2025-11-06 | Q3 2025 | -0.76 | -0.74 | +2.63% | $0 | ✅ Beat | +4.23% | +19.01% | +36.64% |
| 2025-08-11 | Q2 2025 | -0.74 | -0.72 | +2.70% | $0 | ✅ Beat | -0.29% | +5.30% | +10.03% |
| 2025-02-27 | Q4 2024 | -0.91 | -0.67 | +26.37% | $0 | ✅ Beat | -10.97% | -12.53% | -20.54% |
| 2024-08-01 | Q2 2024 | -0.68 | -0.59 | +13.24% | $0 | ✅ Beat | -4.27% | -11.04% | +0.12% |
| 2024-05-07 | Q1 2024 | -0.70 | -0.68 | +2.86% | $0 | ✅ Beat | +12.17% | +17.21% | +26.47% |
Showing last 8 quarters.